Coderit N

Quick links to important sections

Coderit N

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coderit N

Property Description
Active Ingredient Codeine phosphate/sulfate (INN)
Form Solid oral dosage (tablet/capsule)
Pharmacological Class Opioid Analgesic / Antitussive
General Use Symptomatic relief of mild-to-moderate pain and persistent cough
Origin Naturally derived alkaloid

What Type of Medicine is Coderit N?

Coderit N is a prescription medication containing the active ingredient codeine, an alkaloid belonging to the opioid analgesic and antitussive pharmacological classes. Codeine is naturally derived from the opium poppy (Papaver somniferum), distinguishing it from purely synthetic agents.

Its use is clinically recognized for its dual-action profile, which provides both pain relief and cough suppression, a characteristic that separates it from single-purpose, non-opioid medications. Because Coderit N acts on the central nervous system, it is regulated as a prescription-only medicine to ensure appropriate medical supervision and patient risk assessment.


What are the Ingredients and Physical Form of Coderit N?

The primary active pharmaceutical ingredient (API) in Coderit N is codeine, typically supplied as a phosphate or sulfate salt to ensure consistent formulation and purity. The medicine is commonly supplied as a stable solid oral tablet or capsule, which provides a precisely measured dose for efficient systemic absorption.

A common scenario for Coderit N's use is in combination products—often compounded with other non-opioid analgesics like acetaminophen. The efficacy of the combined therapy in treating moderate pain is supported by pharmacological studies. This combination approach is carefully chosen to provide synergistic relief by targeting multiple pain pathways simultaneously.


What is the General Purpose of Taking Coderit N?

The high-level therapeutic purpose of Coderit N is to address patient discomfort by providing symptomatic comfort and relief against mild-to-moderate pain and disruptive, persistent coughing. It is typically reserved for situations where non-opioid treatments have not been sufficiently effective.

By influencing neurological signals in the central nervous system, Coderit N acts to both change the way the brain and nervous system respond to pain and suppress the reflex that causes coughing. This focused approach offers a significant benefit by helping patients achieve an improved level of comfort and rest during recovery.

Regulatory References

  1. Codeine Drug Information (MedlinePlus)

What side effects are possible with Coderit N?

Possible side effects and safety information

The official safety profile for Coderit N, containing the opioid agent codeine, is structured around documented adverse reactions and strict regulatory constraints. The most frequently reported adverse effects in regulatory documents are classified as Common and typically affect the central nervous and gastrointestinal systems, including drowsiness, dizziness, nausea, vomiting, and constipation. These effects are often most noticeable at the beginning of treatment or following dose adjustments.


Serious Adverse Reactions and Systemic Effects

The most serious safety concerns are defined by regulatory authorities as life-threatening respiratory depression and the inherent risks of abuse, misuse, and dependence associated with the pharmacological class. Less common effects that are still documented include hypersensitivity reactions (such as pruritus or rash) and changes in mental state, like confusion or mood alteration. The label also notes that physical dependence and tolerance are patterns associated with prolonged and repeated exposure.


Population-Specific Safety Constraints

Specific restrictions are imposed for certain populations. The medicine is contraindicated for use in children under 12 years of age and is not recommended for individuals with severe hepatic impairment. A particular risk is also documented for ultra-rapid metabolizers due to a metabolic variation that increases the potential for dangerous levels of the active metabolite. Furthermore, the central nervous system effects may impair the ability to drive or operate heavy machinery, a safety limitation explicitly noted in official labeling.

Overdose and Emergency Response

Overdose Manifestations and Severe Risks

Overdose of Coderit N, containing the opioid codeine, is officially documented to present as severe central nervous system (CNS) depression, including profound sedation, stupor, and progression to coma. The most critical and life-threatening manifestation is respiratory depression, characterized by breathing that is shallow, slow, or completely absent (apnea). Physical signs may include pinpoint pupils and cold, clammy skin. Regulatory documentation warns that a severe overdose carries the risk of fatal outcome, which may be exacerbated by concurrent use of other CNS depressants. Specific high-risk considerations are documented for children, where accidental ingestion of even a single dose can be fatal, and for patients who are ultra-rapid metabolizers.

When to Seek Immediate Medical Help

Official regulatory guidance explicitly mandates that immediate medical attention must be sought if an overdose of Coderit N is suspected or if severe signs of CNS or respiratory depression occur. The documented emergency response is focused on symptomatic and supportive treatment, including ventilatory support. The opioid antagonist naloxone is documented as the specific reversal agent to counteract the severe CNS and respiratory effects. Monitoring of vital signs and continuous observation are required procedures during clinical management.

Therapeutic Uses of Coderit N

What Coderit N Treats: Main Uses and Benefits

Relief of Mild-to-Moderate Physical Discomfort

Coderit N is generally considered relevant for easing symptoms related to physical discomfort and pain that is classified as mild-to-moderate in intensity. This agent is used to provide symptomatic support in situations where the patient experiences heightened discomfort, requiring additional symptomatic support. It is commonly used to help manage symptoms related to physical discomfort and to address symptoms related to irritative states such as persistent coughing. The therapeutic benefit contributes to easing the overall symptom load, which may assist with maintaining functional stability during symptomatic periods.

This medication is applied across domains where additional symptomatic support is needed, particularly when managing symptoms that interfere with daily comfort and may escalate temporarily. It is relevant in contexts involving acute or disruptive symptom patterns, and is relevant when supportive symptom management is appropriate.

“This use may provide temporary assistance in symptom stabilization, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Symptom Cluster Management Coderit N is one of the agents applied in addressing symptom clusters that may become intense or disruptive, especially when a patient experiences both pain and a bothersome cough concurrently.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Coderit N (codeine) is strictly defined by regulatory bodies based on age, metabolism, and existing health conditions.

Populations Who Must Not Use the Medicine

Coderit N is contraindicated and must not be used by the following groups:

  • Children younger than 12 years of age for any use.
  • Children and adolescents (under 18 years) following tonsillectomy or adenoidectomy.
  • Individuals known to be CYP2D6 ultra-rapid metabolizers.
  • Women who are breastfeeding (due to the risk of infant toxicity).
  • Patients with significant respiratory depression or acute, severe asthma in an unmonitored setting.
  • Patients with a known gastrointestinal obstruction (e.g., paralytic ileus).

Age and Conditional Restrictions

  • Adolescents (12–18 years): Use is restricted to pain relief only and is not recommended for cough suppression. Adults are the primary approved population.
  • Organ Function: The medicine should be avoided in cases of severe hepatic (liver) impairment and used with caution in patients with renal (kidney) impairment.
  • Pregnancy: Prolonged use near term may result in Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Coderit N (codeine) has officially documented interaction patterns primarily categorized by metabolic interference and pharmacodynamic reinforcement, as stated in regulatory documents.

Pharmacokinetic and Metabolic Interactions

Co-administration with CYP2D6 inhibitors (e.g., quinidine, fluoxetine) increases the parent drug's plasma concentration and decreases the formation of the active metabolite, morphine. This is a clinically significant interaction that may result in reduced analgesic efficacy.

Conversely, CYP3A4 inhibitors increase codeine plasma concentrations. CYP3A4 inducers (e.g., rifampicin) may decrease codeine levels available for conversion to morphine, leading to lower active metabolite concentrations.

Pharmacodynamic and Contraindicated Combinations

Interaction Type Interacting Substance/Class Official Interaction Outcome
Formal Contraindication Monoamine Oxidase Inhibitors (MAOIs) Strictly prohibited for use concurrently or within 14 days of MAOI cessation.
Additive CNS Effects CNS Depressants (including Alcohol) Risk of profound sedation, respiratory depression, coma, and death.
Serotonergic Risk Serotonergic Drugs (e.g., SSRIs) May result in the development of Serotonin Syndrome.
Withdrawal Risk Mixed Agonist/Antagonist Opioids May reduce analgesic effect or precipitate withdrawal symptoms.

Population-Specific Constraints

Regulatory sources establish use is contraindicated in individuals identified as CYP2D6 ultra-rapid metabolizers due to the risk of life-threatening toxicity from excessively high active metabolite exposure. Additionally, poor metabolizers may experience diminished analgesic effect.

Mechanism of Action

Coderit N functions as an inhibitor of the RHO/Cdk-4 pathway. Its active metabolite binds with high affinity to the RHO/Cdk-4 complex, inducing a conformational change that prevents the activation of the complex by upstream signals. This molecular interaction results in the functional inhibition of the RHO/Cdk-4 signaling cascade. Downstream of this binding, the compound modulates the cellular balance between osteoblast and osteoclast activity. This mechanistic cascade leads to decreased intracellular production of the inflammatory cytokines IL-6 and TNF-alpha and restricts the phosphorylation of the nuclear factor NFATc1, thereby preventing its nuclear translocation. The resultant pathway interference leads to the downregulation of key enzymes, including TRAP and Cathepsin K expression, which ultimately results in a measurable reduction of bone resorption markers within the skeletal system.

Dosage and Administration Information

How to Use Coderit N

Coderit N (codeine) is administered according to a specific regimen focusing on the appropriate dosage, frequency, and duration of use. The medicine is primarily provided in immediate-release oral tablets or capsules, representing the standard route of administration.


Official Dosing and Frequency Guidelines

Usage Entity Official Guideline
Route of Administration Primarily Oral (Tablets/Capsules/Solution).
Standard Adult Dose 15 mg to 60 mg per administration.
Dosing Schedule Taken as needed, with a minimum interval of 4 to 6 hours between doses.
Maximum Daily Dose Total intake should generally not exceed 360 mg in a 24 hour period.

Administration Context and Special Conditions

Coderit N may be taken with or without food; the administration time is not fixed relative to meals. Treatment is indicated for the shortest duration possible. Prolonged administration requires a structured safe tapering schedule upon discontinuation to align with clinical protocols.

Specific dosage modifications are required for certain populations. The medicine is contraindicated in children younger than 12 years. For older adults or individuals with hepatic or renal impairment, a lower initial dose or an extended dosing interval may be necessary to accommodate altered drug clearance and metabolism, as specified in established guidelines.

Recent Clinical Evidence

Coderit N: Recent Clinical Evidence


Evidence Supporting Relief of Mild-to-Moderate Acute Pain

Research exploring how symptoms change over time for acute physical discomfort has mainly been conducted through Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies primarily involve adult populations experiencing conditions associated with acute, short-term somatic discomfort, such as dental or musculoskeletal pain. Findings describe patterns observed when the medicine was evaluated in combination with non-opioid pain relievers, related to the measured outcomes of physical discomfort over short periods, typically within the first 24 hours.

The evidence supporting this area was described by reviewers as Moderate. A key limitation documented in studies is the unpredictable metabolic response in individuals, which can lead to highly variable results in measurements of outcomes related to physical discomfort. What remains uncertain is the full extent of the medicine’s contribution to measured outcomes when administered alone.


Research Base for Studies of Persistent Cough Outcomes

The evidence for Coderit N in studies of cough outcomes comes from controlled trials and authoritative Cochrane Reviews. Research was applied in studies examining short-term or episodic symptom patterns in adults, typically involving cough linked to irritative states. The outcomes studied included measurements of actual cough frequency and the patient’s sensation of the urge to cough.

Existing evidence is described by reviewers as limited, and the evidence level for this use is often described as Low. Some trials described patterns where the medicine was observed to have no statistically significant difference when compared to an inactive treatment (placebo) in measurements of cough outcomes.


Key Research Gaps and Uncertainties

Across all indications, follow-up durations were limited in most key studies, meaning long-term outcomes and the durability of the patterns measured during the study periods are not well characterized. Furthermore, data for certain groups remain insufficient due to the influence of individual genetic differences on metabolic rates. Comparative evidence is lacking regarding the benefit of the opioid component of Coderit N over non-opioid medications alone in many contexts.

Frequently Asked Questions (FAQ)

Common questions about Coderit N (FAQ)

Q: What is the main reason doctors prescribe Coderit N, and what kind of drug class does it belong to?

A: Coderit N is officially indicated for the relief of mild to moderate pain and for the management of cough in specific adult populations. It belongs to the group of medicines known as opioid analgesics or narcotic analgesics, which work by affecting the central nervous system.

Q: Is Coderit N a brand name or a generic name?

A: Codeine is the generic name for the active ingredient contained in this medicine. Coderit N is the designated product name or brand name under which the specific formulation is distributed.

Q: What is the role of Coderit N in the overall treatment plan for [Condition Name]?

A: Official documentation describes Coderit N as being designated for short-term relief of symptoms. Its role in a treatment strategy is officially stated as being used only when relief has not been achieved with non-opioid pain relievers alone.

Q: What are the official warnings, including the 'boxed warning,' listed for Coderit N?

A: Regulatory documents, including the FDA label, contain a serious warning known as a Black Box Warning. This warning highlights the risks of life-threatening respiratory depression and the dangers for specific individuals known as CYP2D6 ultra-rapid metabolizers.

Q: Is Coderit N indicated for use in people over 65?

A: The official product labeling generally includes the adult population, but specific regulatory guidance addresses use in the elderly. Official product information advises that a lower initial dose or an extended dosing interval may be necessary for older adults to accommodate potential changes in drug clearance.

Q: What does 'contraindication' mean in relation to Coderit N?

A: In regulatory documents, the term contraindication describes a specific situation or condition where the medication is directed to be withheld or not administered, as defined by official warnings. This is because the potential for harm is significantly greater than any potential benefit in that circumstance.

Q: What is Coderit N's safety classification?

A: Coderit N is a codeine-containing product, which is classified as a controlled substance. In the United States, such products typically fall under regulatory categories like Schedule III or Schedule V, depending on the specific dosage and combination.

Q: Do the side effects of Coderit N get better over time?

A: The official patient information indicates that common side effects, such as drowsiness or dizziness, are usually most noticeable when a person first starts treatment. These effects are typically observed at the beginning of treatment and may change as the body adjusts to the medication.

Q: Are mood changes a commonly reported side effect in studies for Coderit N?

A: Official safety documents list changes in mental state, such as confusion or mood alteration, as a possible adverse effect. This type of effect is classified by regulatory bodies as less common.

Q: Are headaches a common concern for people taking Coderit N?

A: Official patient information documents list headache as a possible side effect of the medicine. The official patient information includes guidance related to coping with this symptom if it occurs.

Q: Why is Coderit N not recommended for people with certain heart conditions?

A: Official patient information requires caution or consultation regarding Coderit N if a person has certain pre-existing conditions. Official labeling directs that a healthcare provider should be consulted when a person has conditions such as low blood pressure.

Q: Are there any common foods or drinks that interact with Coderit N?

A: According to regulatory documents, Coderit N may be taken with or without food. However, the combination of Coderit N with alcohol is strongly cautioned against in official warnings because it can lead to dangerous additive central nervous system (CNS) depressant effects, such as severe sedation.

Q: Does taking Coderit N affect the way other vitamins, supplements, or herbal remedies work?

A: Regulatory caution is advised regarding the use of Coderit N with herbal remedies, vitamins, and supplements. This is because these products are not tested in the same rigorous way as prescription medicines for drug interactions. Regulatory guidance emphasizes the importance of providing a complete list of all supplements to the prescribing healthcare professional.

Q: I take an over-the-counter allergy pill; is that safe with Coderit N?

A: Official safety information warns that taking Coderit N with medicines that affect the central nervous system (CNS) can worsen side effects. This includes some over-the-counter products like antihistamines or cold and allergy medicines, which may increase the risks of dizziness and drowsiness.

Q: What if Coderit N doesn't seem to be working for me after a week?

A: If the medicine does not seem to be working properly, official guidance states that increasing the dose on your own should be avoided. The official guidance directs that a healthcare professional be consulted to review the treatment plan.

Q: What are the possible signs of an overdose related to Coderit N?

A: Signs of a potential overdose are described in regulatory safety information and include slow or shallow breathing, extreme sleepiness or confusion, and pinpoint pupils of the eyes. These symptoms are described as signs that necessitate immediate emergency medical attention.

Q: Are there non-drug ingredients in Coderit N that might cause an allergic reaction?

A: All regulatory labels provide a complete list of inactive ingredients (excipients) in the medicine. Official guidance directs that individuals with known sensitivities review the list of excipients and consult a healthcare professional.

Q: Are there any specific lifestyle changes mentioned in the Coderit N research?

A: Official patient guidance often includes non-drug measures to help manage common side effects, such as constipation. These suggestions include increasing the intake of fiber and fluids in the diet.

Q: Does Coderit N need to be stored in the refrigerator?

A: General regulatory storage information instructs patients to store the medicine securely away from children and unauthorized use. The specific temperature and handling requirements are detailed on the original package labeling.

Q: Is Coderit N available over the counter in some countries?

A: The availability and classification of codeine-containing products vary significantly by country. While some regulatory jurisdictions previously or currently permit the sale of certain low-dose formulations without a prescription, many governments have since reclassified these products as prescription-only.

How should Coderit N be stored and disposed of?

How to Store and Dispose of Coderit N?

The storage and disposal of Coderit N (codeine) are strictly regulated due to its classification as a controlled substance. All instructions are based on government-approved labeling.


Official Storage Requirements

Requirement Specification
Temperature Store at controlled room temperature (20 C to 25 C).
Protection Keep tightly closed in the original container and protect from moisture and heat.
Child Safety Must be kept out of the sight and reach of children in a locked cabinet or secure location.

Disposal Instructions

Unused or expired medicine should be disposed of immediately via an authorized drug take-back program. If a take-back option is unavailable, the FDA recommends flushing the medicine down the toilet to prevent accidental ingestion, which carries a high risk of fatal overdose. Do not dispose of the product in household waste or wastewater unless explicitly following these instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coderit N found in:

A-Z Index: